The p53 reactivator COTI 2 might be efficacious in 22% of tumors, while the other p53 reactivator Eprenetapopt, along with the Wee1 kinase inhibitor IMP-7068 and SGT-53 (a cationic liposomes complex encapsulating human wild-type p53 DNA in a plasmid backbone) may work in 20% of ACC tumors. The gene discussed is TP53; the disease is adrenal cortex carcinoma.